Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib

Multifaceted role of prohibitin in cell survival and apoptosis

(2015) Ya-Ting Peng et al.   APOPTOSIS

Differential effects of peripheral and transitional prostatic stromal cells on tumorigenesis

(2015) Bao Li   Frontiers in Bioscience-Landmark

Vemurafenib for the treatment ofBRAFmutant metastatic melanoma

(2015) Juan Martin-Liberal et al.   Future Oncology

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

(2015) Tu Nguyen-Ngoc et al.   Journal of Thoracic Oncology

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies

(2015) Francesco Spagnolo et al.   OncoTargets and Therapy

Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma

(2014) Zhou Luan et al.   Molecular Cancer

Signaling pathways of prohibitin and its role in diseases

(2013) Tian-Biao Zhou et al.   JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION

BRAF inhibitors in cancer therapy

(2013) Carolina Hertzman Johansson et al.   PHARMACOLOGY & THERAPEUTICS

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors

(2013) Jaehyuk Choi et al.   Pigment Cell & Melanoma Research

The Natural Anticancer Compounds Rocaglamides Inhibit the Raf-MEK-ERK Pathway by Targeting Prohibitin 1 and 2

(2012) Gernot Polier et al.   CHEMISTRY & BIOLOGY

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

(2012) M. Mao et al.   CLINICAL CANCER RESEARCH

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

MAP kinase signaling and inhibition in melanoma

(2012) R J Sullivan et al.   ONCOGENE

Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma

(2012) Molly Yancovitz et al.   PLoS One

Mitochondrial–Nuclear Communication by Prohibitin Shuttling under Oxidative Stress

(2011) Srinivas R. Sripathi et al.   BIOCHEMISTRY

NRAS mutation status is an independent prognostic factor in metastatic melanoma

(2011) John A. Jakob et al.   CANCER

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

(2011) F. Su et al.   CANCER RESEARCH

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

(2011) K. H. T. Paraiso et al.   CANCER RESEARCH

RAF inhibition and induction of cutaneous squamous cell carcinoma

(2011) Caroline Robert et al.   CURRENT OPINION IN ONCOLOGY

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue

(2010) Md. Nazir Hossen et al.   JOURNAL OF CONTROLLED RELEASE

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

The genetic interactome of prohibitins: coordinated control of cardiolipin and phosphatidylethanolamine by conserved regulators in mitochondria

(2009) Christof Osman et al.   JOURNAL OF CELL BIOLOGY

MEK1 mutations confer resistance to MEK and B-RAF inhibition

(2009) C. M. Emery et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells

(2008) N. Doudican et al.   MOLECULAR CANCER RESEARCH

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

(2008) K. S.M. Smalley et al.   MOLECULAR CANCER THERAPEUTICS

Detection of BRAF V600E mutation by pyrosequencing

(2008) Yi Hui Tan et al.   PATHOLOGY